Xpert MTB/XDR: a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum

We describe the design, development, analytical performance, and a limited clinical evaluation of the 10-color Xpert MTB/XDR assay (CE-IVD only, not for sale in the United States). This assay is intended as a reflex test to detect resistance to isoniazid (INH), fluoroquinolones (FLQ), ethionamide (E...

Full description

Saved in:
Bibliographic Details
Main Authors: Cao, Yuan (Author) , Parmar, Heta (Author) , Gaur, Rajiv L. (Author) , Lieu, Deanna (Author) , Raghunath, Shobana (Author) , Via, Nova (Author) , Battaglia, Simone (Author) , Cirillo, Daniela M. (Author) , Denkinger, Claudia M. (Author) , Georghiou, Sophia (Author) , Kwiatkowski, Robert (Author) , Persing, David (Author) , Alland, David (Author) , Chakravorty, Soumitesh (Author)
Format: Article (Journal)
Language:English
Published: 18 February 2021
In: Journal of clinical microbiology
Year: 2021, Volume: 59, Issue: 3, Pages: 1-18
ISSN:1098-660X
DOI:10.1128/JCM.02314-20
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1128/JCM.02314-20
Verlag, lizenzpflichtig, Volltext: https://jcm.asm.org/content/59/3/e02314-20
Get full text
Author Notes:Yuan Cao, Heta Parmar, Rajiv L. Gaur, Deanna Lieu, Shobana Raghunath, Nova Via, Simone Battaglia, Daniela M. Cirillo, Claudia Denkinger, Sophia Georghiou, Robert Kwiatkowski, David Persing, David Alland, Soumitesh Chakravorty

MARC

LEADER 00000caa a2200000 c 4500
001 1753274249
003 DE-627
005 20230426165448.0
007 cr uuu---uuuuu
008 210407s2021 xx |||||o 00| ||eng c
024 7 |a 10.1128/JCM.02314-20  |2 doi 
035 |a (DE-627)1753274249 
035 |a (DE-599)KXP1753274249 
035 |a (OCoLC)1341403664 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Cao, Yuan  |e VerfasserIn  |0 (DE-588)1230906983  |0 (DE-627)1753275229  |4 aut 
245 1 0 |a Xpert MTB/XDR  |b a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum  |c Yuan Cao, Heta Parmar, Rajiv L. Gaur, Deanna Lieu, Shobana Raghunath, Nova Via, Simone Battaglia, Daniela M. Cirillo, Claudia Denkinger, Sophia Georghiou, Robert Kwiatkowski, David Persing, David Alland, Soumitesh Chakravorty 
264 1 |c 18 February 2021 
300 |a 18 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.04.2021 
520 |a We describe the design, development, analytical performance, and a limited clinical evaluation of the 10-color Xpert MTB/XDR assay (CE-IVD only, not for sale in the United States). This assay is intended as a reflex test to detect resistance to isoniazid (INH), fluoroquinolones (FLQ), ethionamide (ETH), and second-line injectable drugs (SLIDs) in unprocessed sputum samples and concentrated sputum sediments which are positive for Mycobacterium tuberculosis. The Xpert MTB/XDR assay simultaneously amplifies eight genes and promoter regions in M. tuberculosis and analyzes melting temperatures (Tms) using sloppy molecular beacon (SMB) probes to identify mutations associated with INH, FLQ, ETH, and SLID resistance. Results can be obtained in under 90 min using 10-color GeneXpert modules. The assay can differentiate low- versus high-level resistance to INH and FLQ as well as cross-resistance versus individual resistance to SLIDs by identifying mutation-specific Tms or Tm patterns generated by the SMB probes. The assay has a limit of detection comparable to that of the Xpert MTB/RIF assay and successfully detected 16 clinically significant mutations in a challenge set of clinical isolate DNA. In a clinical study performed at two sites with 100 sputum and 214 clinical isolates, the assay showed a sensitivity of 94% to 100% and a specificity of 100% for all drugs except for ETH compared to that of sequencing. The sensitivity and specificity were in the same ranges as those of phenotypic drug-susceptibility testing. Used in combination with a primary tuberculosis diagnostic test, this assay should expand the capacity for detection of drug-resistant tuberculosis near the point of care. 
700 1 |a Parmar, Heta  |e VerfasserIn  |4 aut 
700 1 |a Gaur, Rajiv L.  |e VerfasserIn  |4 aut 
700 1 |a Lieu, Deanna  |e VerfasserIn  |4 aut 
700 1 |a Raghunath, Shobana  |e VerfasserIn  |4 aut 
700 1 |a Via, Nova  |e VerfasserIn  |4 aut 
700 1 |a Battaglia, Simone  |e VerfasserIn  |4 aut 
700 1 |a Cirillo, Daniela M.  |e VerfasserIn  |4 aut 
700 1 |a Denkinger, Claudia M.  |d 1978-  |e VerfasserIn  |0 (DE-588)131597701  |0 (DE-627)511279469  |0 (DE-576)298613727  |4 aut 
700 1 |a Georghiou, Sophia  |e VerfasserIn  |4 aut 
700 1 |a Kwiatkowski, Robert  |e VerfasserIn  |4 aut 
700 1 |a Persing, David  |e VerfasserIn  |4 aut 
700 1 |a Alland, David  |e VerfasserIn  |4 aut 
700 1 |a Chakravorty, Soumitesh  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical microbiology  |d Washington, DC : Soc., 1975  |g 59(2021), 3, Artikel-ID e02314-20, Seite 1-18  |h Online-Ressource  |w (DE-627)306587963  |w (DE-600)1498353-9  |w (DE-576)095092048  |x 1098-660X  |7 nnas  |a Xpert MTB/XDR a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum 
773 1 8 |g volume:59  |g year:2021  |g number:3  |g elocationid:e02314-20  |g pages:1-18  |g extent:18  |a Xpert MTB/XDR a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum 
856 4 0 |u https://doi.org/10.1128/JCM.02314-20  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://jcm.asm.org/content/59/3/e02314-20  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210407 
993 |a Article 
994 |a 2021 
998 |g 131597701  |a Denkinger, Claudia M.  |m 131597701:Denkinger, Claudia M.  |d 910000  |d 911700  |d 50000  |e 910000PD131597701  |e 911700PD131597701  |e 50000PD131597701  |k 0/910000/  |k 1/910000/911700/  |k 0/50000/  |p 9 
999 |a KXP-PPN1753274249  |e 3903112046 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 07.04.2021"],"relHost":[{"title":[{"title":"Journal of clinical microbiology","title_sort":"Journal of clinical microbiology"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"American Society for Microbiology"}],"id":{"zdb":["1498353-9"],"issn":["1098-660X"],"eki":["306587963"]},"origin":[{"publisherPlace":"Washington, DC","publisher":"Soc.","dateIssuedKey":"1975","dateIssuedDisp":"1975-"}],"disp":"Xpert MTB/XDR a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputumJournal of clinical microbiology","name":{"displayForm":["American Society for Microbiology"]},"recId":"306587963","pubHistory":["1.1975 -"],"note":["Gesehen am 08.06.2021","Fortsetzung der Druck-Ausgabe"],"part":{"extent":"18","text":"59(2021), 3, Artikel-ID e02314-20, Seite 1-18","pages":"1-18","volume":"59","issue":"3","year":"2021"}}],"person":[{"family":"Cao","role":"aut","given":"Yuan","display":"Cao, Yuan"},{"family":"Parmar","role":"aut","given":"Heta","display":"Parmar, Heta"},{"role":"aut","given":"Rajiv L.","family":"Gaur","display":"Gaur, Rajiv L."},{"display":"Lieu, Deanna","given":"Deanna","role":"aut","family":"Lieu"},{"family":"Raghunath","given":"Shobana","role":"aut","display":"Raghunath, Shobana"},{"display":"Via, Nova","family":"Via","role":"aut","given":"Nova"},{"display":"Battaglia, Simone","role":"aut","given":"Simone","family":"Battaglia"},{"display":"Cirillo, Daniela M.","role":"aut","given":"Daniela M.","family":"Cirillo"},{"display":"Denkinger, Claudia M.","given":"Claudia M.","role":"aut","family":"Denkinger"},{"display":"Georghiou, Sophia","family":"Georghiou","role":"aut","given":"Sophia"},{"display":"Kwiatkowski, Robert","role":"aut","given":"Robert","family":"Kwiatkowski"},{"display":"Persing, David","family":"Persing","role":"aut","given":"David"},{"family":"Alland","role":"aut","given":"David","display":"Alland, David"},{"role":"aut","given":"Soumitesh","family":"Chakravorty","display":"Chakravorty, Soumitesh"}],"title":[{"title":"Xpert MTB/XDR","subtitle":"a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from mycobacterium tuberculosis-positive sputum","title_sort":"Xpert MTB/XDR"}],"physDesc":[{"extent":"18 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1128/JCM.02314-20"],"eki":["1753274249"]},"origin":[{"dateIssuedDisp":"18 February 2021","dateIssuedKey":"2021"}],"name":{"displayForm":["Yuan Cao, Heta Parmar, Rajiv L. Gaur, Deanna Lieu, Shobana Raghunath, Nova Via, Simone Battaglia, Daniela M. Cirillo, Claudia Denkinger, Sophia Georghiou, Robert Kwiatkowski, David Persing, David Alland, Soumitesh Chakravorty"]},"recId":"1753274249"} 
SRT |a CAOYUANPARXPERTMTBXD1820